Anti-CD3-anti-CD19 bispecific monoclonal antibody
Alternative Names: Monoclonal antibody SHR-1Latest Information Update: 10 Apr 2003
At a glance
- Originator Unknown
- Developer Nonindustrial source
- Class Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD19 antigen inhibitors; CD3 antigen inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lymphoid leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 10 Apr 2003 No development reported - Phase-I for Non-Hodgkin's lymphoma in Netherlands (IV-infusion)
- 10 Apr 2003 No development reported - Phase-I for Non-Hodgkin's lymphoma in United Kingdom (IV-infusion)
- 10 Apr 2003 No development reported - Preclinical for Lymphoid leukaemia in Germany (IV-infusion)